Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
Countdown to Axsome (AXSM) Q2 Earnings: Wall Street Forecasts for Key Metrics
10:16am, Wednesday, 05'th Aug 2026
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Axsome (AXSM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quar
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
11:01am, Monday, 03'rd Aug 2026
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for July 31st
05:52am, Friday, 31'st Jul 2026
BLND, AXSM and BCML have been added to the Zacks Rank #5 (Strong Sell) List on July 31, 2026.
New Strong Sell Stocks for July 29th
06:31am, Wednesday, 29'th Jul 2026
ARDX, BDORY and AXSM have been added to the Zacks Rank #5 (Strong Sell) List on July 29, 2026.
New Strong Sell Stocks for July 27th
06:38am, Monday, 27'th Jul 2026
LEN, AXSM and SAM have been added to the Zacks Rank #5 (Strong Sell) List on July 27, 2026.
Caxton Associates LLP Makes New Investment in Axsome Therapeutics, Inc. $AXSM
03:54am, Monday, 27'th Jul 2026
Caxton Associates LLP bought a new stake in Axsome Therapeutics, Inc. (NASDAQ: AXSM) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The
These major drug stocks rally after Trump's zero tariff announcement
06:31am, Wednesday, 22'nd Jul 2026
President Donald Trump has announced that all generic drugs imported into the United States would continue to enjoy a zero-percent tariff for another two years, sending major drug stocks up.
Axsome's NDA for AXS-12 in Narcolepsy Gets FDA Acceptance
01:01pm, Thursday, 16'th Jul 2026
AXSM advances AXS-12 toward potential approval after the FDA accepts its NDA for cataplexy in narcolepsy and sets a May 2027 decision date.
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
07:00am, Wednesday, 15'th Jul 2026
FDA sets PDUFA target action date of May 1, 2027 NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
07:00am, Tuesday, 14'th Jul 2026
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an
3 Under-the-Radar Stocks to Buy and Hold
02:30pm, Friday, 10'th Jul 2026
These three biotechs are posting strong revenue growth. Brand-new launches and label expansions should help them improve their lineups.
Better Growth Buy: Axsome vs Revolution Medicines
03:55am, Thursday, 09'th Jul 2026
Axsome has a solid late-stage pipeline and growing commercialized drugs. Revolution aims to revolutionize cancer treatment, and a recent phase 3 trial shows it may be on the right path.
Axsome Begins Phase III Study on Solriamfetol for ADHD in Children
12:20pm, Wednesday, 08'th Jul 2026
AXSM doses the first patient in the phase III FOCUS-2 study of solriamfetol for treating ADHD in children aged six to under 12 years.
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
07:00am, Tuesday, 07'th Jul 2026
The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHD NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharm
These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More
06:10pm, Monday, 06'th Jul 2026
Each of these biotech players has reached an important turning point. Recent drug approvals could supercharge the performance of one in particular.
